Hydrocortisone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Hydrocortisone: From Adrenal Insufficiency to Alopecia Areata
Disclaimer: This report is for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before use. This report was generated by the TxGNN drug repurposing system (data cutoff: 2026-04-04).
One-Sentence Summary
Hydrocortisone is the synthetic form of the endogenous glucocorticoid cortisol, used clinically for adrenal insufficiency, inflammatory conditions, and allergic reactions. The TxGNN model predicts it may be effective for Alopecia Areata, with 4 clinical trials and 20 publications currently supporting this direction. The highest-grade evidence includes a completed Phase 3 RCT directly comparing hydrocortisone 1% cream to a higher-potency corticosteroid in paediatric patients with this condition.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Adrenal insufficiency, inflammatory and allergic conditions (no SAHPRA registration found in current database) |
| Predicted New Indication | Alopecia Areata |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L1 |
| South Africa Market Status | Not found in SAHPRA database |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Hydrocortisone is a glucocorticoid that binds to the intracellular glucocorticoid receptor (GR) and inhibits the NF-κB signalling pathway, resulting in broad downregulation of pro-inflammatory cytokines including IL-2, IFN-γ, and TNF-α. It is one of the oldest and most pharmacologically well-characterised anti-inflammatory agents in clinical medicine, forming the basis of corticosteroid therapy across many disciplines.
Alopecia areata (AA) is an autoimmune condition in which CD8+ T cells infiltrate hair follicles and disrupt the normal “immune privilege” of the follicular bulb. The pathological cytokine signature of AA — elevated IFN-γ, IL-2, and TNF-α — precisely mirrors the targets of topical glucocorticoid therapy. This mechanistic alignment is the core pharmacological rationale for using corticosteroids in AA, and it directly explains why TxGNN identifies hydrocortisone as a strong candidate.
Critically, this is not a novel or theoretical repurposing proposal. A completed Phase 3 RCT (NCT01453686; published as PMID 24226568 in JAMA Dermatology, 2014) directly evaluated hydrocortisone 1% cream versus clobetasol propionate 0.05% cream in paediatric alopecia areata. The results confirmed that hydrocortisone 1% is clinically active, though of lower potency than high-strength corticosteroids. Historical clinical literature dating from the 1950s–1960s further documents hair regrowth following intradermal hydrocortisone injections in AA and alopecia totalis (PMIDs 13368875, 13610145, 5989830, 14158891). Hydrocortisone’s role is therefore best understood as a lower-potency, safer option — especially in children and patients with mild or limited-patch disease — within the broader corticosteroid treatment paradigm for AA.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01453686 | Phase 3 | Completed | 41 | Head-to-head RCT: Clobetasol propionate 0.05% cream vs Hydrocortisone 1% cream in children with alopecia areata. Hydrocortisone demonstrated measurable efficacy as the lower-potency comparator; supports its specific role in paediatric or mild cases where high-potency steroid risks (skin atrophy, HPA suppression) are a concern |
| NCT00484679 | Phase 2 | Completed | 18 | Assessed the impact of intralesional Triamcinolone Acetonide 10 mg/mL on adrenal gland function in alopecia areata patients. Indirect safety context for corticosteroid use in AA; uses a different (higher-potency) corticosteroid but informs class-level HPA safety assessment |
| NCT06551818 | N/A | Not Yet Recruiting | 72 | Prospective double-blind four-arm dose-response study of hair growth products in androgenic alopecia (Grade I–III); exploratory design, targets a different alopecia subtype, results pending — limited direct applicability to AA |
| NCT04343560 | N/A | Completed | 380 | Large study examining the effect of abnormal steroid metabolome (mild autonomous cortisol secretion) on bone quality and density. Provides background safety data on long-term endogenous cortisol excess; indirectly informs the risk profile of exogenous glucocorticoid use |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24226568 | 2014 | RCT | JAMA Dermatology | Randomised clinical trial (n=41 children): Hydrocortisone 1% cream vs clobetasol propionate 0.05% cream for alopecia areata. Hydrocortisone confirmed as clinically active; lower potency than clobetasol, supporting its use in mild disease and paediatric populations |
| 38501938 | 2024 | Systematic Review | Clinical and Experimental Dermatology | Retrospective single-centre analysis of topical corticosteroids under occlusion for severe AA (including alopecia totalis and universalis) in children; demonstrates meaningful response rates and supports corticosteroid use in refractory paediatric cases |
| 36718837 | 2023 | Systematic Review / Meta-analysis | Journal of Cosmetic Dermatology | Meta-analysis of fractional laser alone and in combination with other treatments (including corticosteroids) for alopecia areata; contextualises topical steroids within the current therapeutic landscape |
| 13368875 | 1956 | Historical Clinical Trial | Medical Times | Foundational clinical trial evaluating cortisone, hydrocortisone, prednisone, and prednisolone in alopecia areata partialis, areata, and totalis; establishes glucocorticoids as an effective class for all severity levels of AA |
| 13610145 | 1958 | Clinical Report | Der Hautarzt | Documents hair regrowth in alopecia areata and alopecia maligna following intracutaneous hydrocortisone injections; early direct evidence for intralesional route |
| 5989830 | 1966 | Clinical Study | Vestnik Dermatologii | Reports outcomes of intracutaneous hydrocortisone injections for both alopecia areata and total alopecia; supports the intralesional hydrocortisone approach |
| 14158891 | 1963 | Clinical Report | Actas Dermo-Sifiliográficas | Reports use of intradermal hydrocortisone injections for alopecia areata treatment; corroborates the multi-decade clinical history of this approach |
| 28516731 | 2017 | Review | JEADV | Reviews the role of the hypothalamic-pituitary-adrenal (HPA) axis — including cortisol and MSH — in alopecia areata; provides mechanistic insight into why endogenous glucocorticoid signalling is relevant to AA pathogenesis |
| 39506493 | 2025 | Exploratory Clinical Study | Journal of Cosmetic Dermatology | Explores impact of chronic psychological stress on skin ageing; highlights cortisol as a mediator of dermatoses including AA, acne, and psoriasis — supports the stress-cortisol-immune axis as a mechanistic bridge |
| 15692503 | 2005 | Case Report | JAAD | Four cases of congenital alopecia areata with 3–5 years follow-up; treatment included topical minoxidil 2% and a range of topical corticosteroids, with documented periods of hair quiescence |
South Africa Market Information
No SAHPRA registrations for Hydrocortisone were found in the current database (0 registrations; market status: not found).
Important note: This data finding is likely a database gap rather than reflecting the actual regulatory situation. Hydrocortisone is a long-established corticosteroid included on the WHO Essential Medicines List and is widely available in South Africa in topical, oral, and parenteral formulations. Healthcare professionals should verify current SAHPRA registration status and approved formulations (including topical cream 1% relevant to this indication) directly via the SAHPRA online register or through a registered pharmacy.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for full safety information. Report adverse drug reactions to SAHPRA via the MedSafety reporting portal.
Clinically important safety signals specific to this indication:
- HPA axis suppression: Topical hydrocortisone — particularly under occlusion or with extended use over large body surface areas — carries a risk of systemic glucocorticoid absorption and HPA axis suppression, especially in children. Monitor growth and adrenal function with prolonged use.
- Skin atrophy and telangiectasia: A recognised complication of prolonged topical corticosteroid use on the scalp and face.
- Contraindication in Telogen Effluvium: Excess glucocorticoid exposure (including from exogenous hydrocortisone) is a known precipitant of telogen effluvium. Hydrocortisone is therefore contraindicated for use in telogen effluvium and should not be confused with or used for that diagnosis.
- Caution in Folliculitis Decalvans: Corticosteroid monotherapy carries a risk of worsening infection in Staphylococcus aureus-driven scarring alopecias. Antibiotic co-therapy is required if corticosteroids are considered.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 3 RCT (PMID 24226568, JAMA Dermatology 2014) directly supports the use of hydrocortisone 1% cream for alopecia areata in paediatric patients, and the mechanistic link between glucocorticoid receptor activation and AA immunopathology is well-established across decades of clinical and laboratory literature. The evidence base is sufficient to recommend clinical use with appropriate guardrails, recognising that hydrocortisone 1% is best suited to mild or limited-patch AA and paediatric patients, while moderate-to-severe adult cases may require higher-potency corticosteroids or advanced therapies (e.g., JAK inhibitors).
To proceed, the following is needed:
- Verify SAHPRA registration: Confirm that hydrocortisone topical cream 1% is currently registered and available in South Africa; if no appropriate topical formulation is registered, a special access mechanism or compounding pathway should be considered
- Obtain full MOA documentation: Retrieve complete mechanism of action and pharmacological class data from DrugBank (DB00741) to finalise safety and interaction profiling
- Define patient population: Restrict initial use to mild, limited-patch AA or paediatric patients where the lower potency of hydrocortisone 1% is appropriate and its safety advantages over high-potency corticosteroids are most relevant
- Safety monitoring plan: Establish monitoring parameters for HPA axis function (especially in children with prolonged use), skin atrophy surveillance, and criteria for step-up to higher-potency agents
- Formulation and route strategy: Confirm topical cream as the primary route; evaluate whether intralesional hydrocortisone (supported by historical literature) offers any advantage over the more commonly used intralesional triamcinolone acetonide in the local clinical context
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.